Drugs / tetanus peptide melanoma vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00071981 | May 2005 → Aug 2011 | cutaneous melanoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00003222 | Apr 1998 → Sep 2003 | cutaneous melanoma | University of Virginia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tetanus peptide melanoma vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00071981 ↗ |
| Modality | Peptide | “plus a tetanus helper peptide” PMID 14581425 ↗ Nov 2003 |
| Route | Subcutaneous | “1 tetanus peptide melanoma vaccine emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC” NCT00071981 ↗ |